Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: In May 2023, when the WHO declared that COVID-19 was no longer a public health emergency of international concern, countries began considering transitioning from the emergency phase to routine provision of COVID-19 vaccination. This paper presents the experience of seven countries with integrating COVID-19 vaccination into other health services and health system functions.

Methods: Data collection took place between August 2023 and April 2024 in Benin, Ethiopia, Ghana, India (Tamil Nadu State), Liberia, Mozambique and Nigeria using key informant interviews and focus group discussions. Interviewees included national and subnational representatives from across the Ministry of Health, COVID-19 task forces, civil society organisations and partners. Focus group discussions were conducted with health workers.

Results: While demand for vaccination was low at the time of data collection, six of seven countries had started integrating or planned to integrate COVID-19 vaccination with other health services. Relatively high integration was reported for certain health system functions such as supply chain, while others such as information systems were less integrated. The immunisation programme served as lead on integrating COVID-19 vaccination, but coordinating across other health programmes was a major challenge. Nearly all assessment countries relied on external funding for COVID-19 vaccines; none had plans to self-procure COVID-19 vaccines when external funding ends.

Conclusion: This article highlights challenges such as a lack of cross-programmatic coordination with clear roles and accountability mechanisms, absence of a clear strategy for sustainable procurement of COVID-19 vaccines, infodemics, as well as considerations countries face in transitioning from emergency response to a more routine approach to COVID-19 vaccination. Opportunities exist to focus COVID-19 vaccination integration efforts in a way that sets the stage for a strengthened life course approach to immunisation; lessons for future emergencies include designing for integration earlier to ensure systems and processes built are leveraged postemergency.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382493PMC
http://dx.doi.org/10.1136/bmjgh-2024-017035DOI Listing

Publication Analysis

Top Keywords

covid-19 vaccination
28
integrating covid-19
12
vaccination health
12
covid-19 vaccines
12
covid-19
11
health
9
vaccination
8
transitioning emergency
8
health services
8
health system
8

Similar Publications

B cell dysregulation during acute COVID-19 is transient.

Immunol Lett

September 2025

Department of Bacteriology and Immunology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; HUS Diagnostic Center, Clinical Microbiology, Helsinki University Hospital, Helsinki,

Background: COVID-19 is still a significant health concern worldwide. B cell responses to COVID-19 have been extensively studied in acute severe disease, but less so during extended follow-up or mild disease. Persisting immunological changes together with herpesvirus reactivations during acute COVID-19 have been suggested as contributing factors for post-acute sequelae of COVID-19 (PASC).

View Article and Find Full Text PDF

Spillover of SARS-CoV-2 to Domestic Dogs in COVID-19-Positive Households: A One Health Surveillance Study.

Virus Res

September 2025

Pennsylvania Department of Agriculture, Pennsylvania Veterinary Laboratory, Harrisburg, PA 17110, USA. Electronic address:

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is capable of infecting multiple species through human-to-animal spillover. Human to animal spillovers have been documented both in domestic and wild animal species. Due to close contact in shared households, pet dogs may be at increased risk for contracting the SARS-CoV-2 virus from infected individuals in the same household.

View Article and Find Full Text PDF

Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.

Int J Infect Dis

September 2025

University of San Francisco, Department of Nursing and Health Professions, San Francisco, California, United States; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Department of Epidemiology, Fielding School of Public Health, University of California, Los A

Objectives: To quantify the incidence of adverse events given COVID-19 vaccination and COVID-19 diagnosis in women of reproductive age; to examine pregnancy as a potential risk modifier.

Methods: An exposure-matched cohort study of >1 million women, 11 December 2020-30 September 2022, United States. COVID-19 vaccination, COVID-19 diagnoses, and medically-attended adverse events - including immunologic, neurologic, cerebrovascular, thromboembolic, cardiovascular, respiratory, thrombocytopenic and coagulative events - were identified from inpatient and outpatient medical claims.

View Article and Find Full Text PDF

Mapping the infectious burden in VEXAS syndrome: a systematic review and rationale for prevention.

Lancet Rheumatol

September 2025

Service de Médecine interne et polyvalente, Centre Hospitalier du Haut-Anjou, Château-Gontier, France; Université d'Angers, Inserm, CNRS, MITOVASC, Equipe MitoLab, SFR ICAT, F-49000 Angers, France. Electronic address:

Infections are increasingly recognised as a major cause of morbidity and mortality in patients with vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. We conducted a systematic review to characterise the infectious burden of VEXAS syndrome and propose preventive strategies. We included 57 studies (813 patients) showing that infections in patients with VEXAS syndrome were frequent, severe in 40-60% of cases, and fatal in 6-15% of cases.

View Article and Find Full Text PDF

Objectives: Contribute to data on the long-term real-world effectiveness of the BNT162b2 vaccine efficacy (VE) in adolescents.

Study Design: This observational study from July 2021 to June 2022 was designed to emulate a target trial.

Methods: Fully vaccinated adolescents 12-15 years of age were matched to unvaccinated adolescents.

View Article and Find Full Text PDF